Mylan NV (MYL) finalized a $465 million settlement with the U.S. Department of Justice, bringing an end to a suit over claims the drug maker overcharged the government for its EpiPen emergency allergy treatment, Reuters reported.

The U.S. Attorney's Office in Massachusetts revealed the deal Thursday, 10 months after it was solidified. Mylan maintained it had done nothing wrong, but the government said taxpayers expect "companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules."

The government claimed Mylan misclassified the EpiPen as a generic rather than a branded prescription to avoid paying rebates to Medicaid after French rival Sanofi SA (SNY) went to the authorities in 2015. Sanofi will get nearly $38.8 million as a reward from the government.

Mylan stock traded up 1.5% to $30.93 midday Thursday.

Mylan isn't the only drug maker working itself out of hot water. Valeant (VRX) still has to prove it can pay down its debt. 

More of What's Trending on TheStreet:

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids